Ambu A/S
CSE:AMBU B
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Q
|
Qliro AB
STO:QLIRO
|
SE |
|
W
|
Wuhan Kotei Informatics Co Ltd
SZSE:301221
|
CN |
|
B
|
Beijing Beilu Pharmaceutical Co Ltd
SZSE:300016
|
CN |
|
Medialink Group Ltd
HKEX:2230
|
HK |
|
Vaibhav Global Ltd
NSE:VAIBHAVGBL
|
IN |
|
L E Lundbergforetagen AB (publ)
STO:LUND B
|
SE |
Ambu A/S
EPS (Diluted)
Ambu A/S
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Ambu A/S
CSE:AMBU B
|
EPS (Diluted)
kr2
|
CAGR 3-Years
75%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
GN Store Nord A/S
CSE:GN
|
EPS (Diluted)
kr4
|
CAGR 3-Years
4%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-1%
|
|
|
Demant A/S
CSE:DEMANT
|
EPS (Diluted)
kr7
|
CAGR 3-Years
-7%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
|
V
|
ViroGates A/S
CSE:VIRO
|
EPS (Diluted)
-kr1
|
CAGR 3-Years
22%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
Ambu A/S
Glance View
Ambu A/S, a Danish company rooted in innovation, has carved a niche in the global healthcare sector through its specialized medical devices. Founded in 1937, Ambu started with a simple mission of improving patient care and has stayed true to that vision by continuously advancing their portfolio. The company's journey began with the invention of the resuscitator bag, a revolutionary product that remains a staple in emergency and hospital settings today. Over the years, Ambu has focused strategically on three main segments: Anesthesia, Patient Monitoring & Diagnostics, and Visualisation, each playing a crucial role in the broader healthcare ecosystem. These segments allow Ambu to develop devices that enhance diagnostic procedures, improve safety, and increase efficiency in medical settings, ultimately saving lives and optimizing healthcare delivery. Ambu’s business model capitalizes primarily on innovation-driven sales, with a strong emphasis on disposable medical devices which are gaining popularity due to hygiene concerns and regulatory trends favoring single-use technologies. These products include their flagship single-use endoscopes, marketed under the brand name "Ambu aScope," which significantly reduce the risk of cross-contamination while providing high-quality diagnostic images. The company's revenue model is built on a B2B approach, dealing directly with hospitals, clinics, and other healthcare providers, ensuring a steady flow of sales through long-term contracts and partnerships. Through constant reinvestment into R&D and strategic acquisitions, Ambu sustains its market leadership, driving growth by addressing the evolving needs of the healthcare industry and setting standards in patient care solutions globally.
See Also
What is Ambu A/S's EPS (Diluted)?
EPS (Diluted)
2
DKK
Based on the financial report for Dec 31, 2025, Ambu A/S's EPS (Diluted) amounts to 2 DKK.
What is Ambu A/S's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
12%
Over the last year, the EPS (Diluted) growth was 69%. The average annual EPS (Diluted) growth rates for Ambu A/S have been 75% over the past three years , 12% over the past five years .